Cerner, a health IT firm with more than 5,000 employees and nearly $1 billion in annual revenues, has entered the bioinformatics market with the launch of its latest informatics offering.

The technology, called PathNet Helix, was released last week and targets the emerging clinical genomics market. Though big IT players like IBM and HP, as well as a number of smaller bioinformatics startups, have set their sights on this market, Cerner is approaching the technology and the market from a different direction — which may give it an important advantage.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.